Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hazel Breitz

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Cancer Biotherapy & Radiopharmaceuticals|March 28, 2002
Dosimetry in a myeloablative settingHazel Breitz
Cancer Biotherapy & Radiopharmaceuticals|August 3, 2004
Clinical aspects of radiation nephropathyHazel Breitz
Cancer Biotherapy & Radiopharmaceuticals|June 14, 2003
Dosimetry of high dose skeletal targeted radiotherapy (STR) with 166Ho-DOTMPHazel Breitz, Richard Wendt, Michael Stabin, et al.
Cancer Biotherapy & Radiopharmaceuticals|August 3, 2004
Dosimetry model for radioactivity localized to intestinal mucosaDarrell Fisher, Didier Rajon, Hazel Breitz, et al.
Cancer Biotherapy & Radiopharmaceuticals|March 22, 2005
Testicular uptake and radiation dose in patients receiving Zevalin and Pretarget CC49Fusion proteinSui Shen, Ruby Meredith, Jun Duan, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 6, 2005
Patient-specific dosimetry of pretargeted radioimmunotherapy using CC49 fusion protein in patients with gastrointestinal malignanciesSui Shen, Andres Forero, Albert F LoBuglio, et al.
Blood|May 6, 2003
166Ho-DOTMP plus melphalan followed by peripheral blood stem cell transplantation in patients with multiple myeloma: results of two phase 1/2 trialsSergio Giralt, William Bensinger, Mark Goodman, et al.
Cancer Biotherapy & Radiopharmaceuticals|August 24, 2005
Pretargeted radioimmunotherapy (RIT) with a novel anti-TAG-72 fusion proteinAndres Forero-Torres, Sui Shen, Hazel Breitz, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 24, 2007
Results of a retrospective single institution analysis of targeted skeletal radiotherapy with (166)Holmium-DOTMP as conditioning regimen for autologous stem cell transplant for patients with multiple myeloma. Impact on transplant outcomesAnna V Christoforidou, Rima M Saliba, Patricia Williams, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Cancer Biotherapy & Radiopharmaceuticals|March 28, 2002
Dosimetry in a myeloablative settingHazel Breitz
Cancer Biotherapy & Radiopharmaceuticals|August 3, 2004
Clinical aspects of radiation nephropathyHazel Breitz
Cancer Biotherapy & Radiopharmaceuticals|June 14, 2003
Dosimetry of high dose skeletal targeted radiotherapy (STR) with 166Ho-DOTMPHazel Breitz, Richard Wendt, Michael Stabin, et al.
Cancer Biotherapy & Radiopharmaceuticals|August 3, 2004
Dosimetry model for radioactivity localized to intestinal mucosaDarrell Fisher, Didier Rajon, Hazel Breitz, et al.
Cancer Biotherapy & Radiopharmaceuticals|March 22, 2005
Testicular uptake and radiation dose in patients receiving Zevalin and Pretarget CC49Fusion proteinSui Shen, Ruby Meredith, Jun Duan, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 6, 2005
Patient-specific dosimetry of pretargeted radioimmunotherapy using CC49 fusion protein in patients with gastrointestinal malignanciesSui Shen, Andres Forero, Albert F LoBuglio, et al.
Blood|May 6, 2003
166Ho-DOTMP plus melphalan followed by peripheral blood stem cell transplantation in patients with multiple myeloma: results of two phase 1/2 trialsSergio Giralt, William Bensinger, Mark Goodman, et al.
Cancer Biotherapy & Radiopharmaceuticals|August 24, 2005
Pretargeted radioimmunotherapy (RIT) with a novel anti-TAG-72 fusion proteinAndres Forero-Torres, Sui Shen, Hazel Breitz, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 24, 2007
Results of a retrospective single institution analysis of targeted skeletal radiotherapy with (166)Holmium-DOTMP as conditioning regimen for autologous stem cell transplant for patients with multiple myeloma. Impact on transplant outcomesAnna V Christoforidou, Rima M Saliba, Patricia Williams, et al.
Pageof 1